Selective cyclooxygenase-2 inhibition reduces endothelial dysfunction and improves inflammatory status in patients with intermittent claudication;La inhibición selectiva de la ciclooxigenasa-2 mejora la disfunción endotelial y disminuye el estado inflamatorio en pacientes claudicantes

Revista Espanola de Cardiologia

Volumn 62, Issue 8, 2009, Pages 851-857

  Flórez, Aurora ^a   De Haro, Joaquín ^a   Martínez, Esther ^a   Varela, César ^a   Bleda, Silvia ^a   Acín, Francisco ^a  

^a HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

Author keywords

Atherosclerosis; Endothelin; Endothelium; Inflammation; Peripheral arterial disease

Indexed keywords

C REACTIVE PROTEIN; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ENDOTHELIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTERY DISEASE; ARTICLE; ATHEROSCLEROSIS; BRACHIAL ARTERY; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; INTERMITTENT CLAUDICATION; LIPID ANALYSIS; MALE; PROTEIN BLOOD LEVEL; TREATMENT DURATION;

CYCLOOXYGENASE 2 INHIBITORS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; INFLAMMATION; INTERMITTENT CLAUDICATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRAZOLES; SULFONAMIDES;

EID: 70349119149     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1016/S0300-8932(09)72067-6     Document Type: Article

References (34)

1. J. Davignon, and P. Ganz Role of endothelial dysfunction in atherosclerosis Circulation 110 Suppl 3 2004 27 32 (Pubitemid 38786440)
2. W.L. Smith, and L.J. Marnett Prostaglandin endoperoxide synthase: structure and catalysis Biochem Biophys Acta 1083 1991 1 17
3. R.N. Dubois, S.B. Abramson, L. Crofford, R.A. Gupta, L.S. Simon, and L.B. Van De Putte Cyclooxygenase in biology and disease FASEB J 12 1998 1063 1073 (Pubitemid 28418937)
4. T. Hla, and K. Nielson Human cyclo-oxygenase-2 cDNA Proc Natl Acad Sci U S A 89 1992 7384 7388
5. A. Raz, A. Wyche, N. Siegel, and P. Needleman Regulation of fibroblast cyclooxygenase synthesis by interleukin-1 J Biol Chem 263 1988 3022 3028 (Pubitemid 18062959)
6. U. Schönbeck, G.K. Sukhova, P. Graber, S. Coulter, and P. Libby Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions Am J Pathol 155 1999 1281 1291 (Pubitemid 29488935)
7. C. Bombardier, L. Laine, and A. Reicin Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis N Engl J Med 343 2000 1520 1528 (Pubitemid 30844348)
8. M. Farooq, I. Haq, and A.S. Qureshi Cardiovascular risks of COX inhibition: current perspectives Expert Opin Pharmacother 9 2008 1311 1319 (Pubitemid 351877515)
9. W.B. White, C.R. West, J.S. Borer, P.B. Gorelick, L. Lavange, and S.X. Pan Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials Am J Cardiol 99 2007 91 98 (Pubitemid 44969347)
10. J. Martínez-González, and L. Badimon Mechanisms underlying the cardiovascular effects of COX-2 inhibition: benefits and risks Curr Pharm Des 13 2007 2215 2227 (Pubitemid 47321572)
11. E.S. Krul, N. Napawan, D.T. Butteiger, K. Hayes, L. Krause, and G.E. Freidrich et al. Atherosclerosis is reduced in cholesterolfed Apo E (-/-) mice administered an ASBT inhibitor or a selective COX-2 inhibitor Arterioscler Thromb Vasc Biol 22 2002 409 412
12. M.E. Widlansky, D.T. Price, N. Gokce, R.T. Eberhardt, S.J. Duffy, and M. Holbrook Short and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension Hypertension 42 2003 310 315 (Pubitemid 37093478)
13. R. Chenevard, D. Hürlimann, M. Béchir, F. Enseleit, L. Spieker, and M. Hermann et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease Circulation 107 2003 405 409
14. Medina FJ, De Haro J, March JR, Martínez E, López-Quintana A, Acín F. Relationship between noninvasively measured endothelial function and peripheral arterial disease. Angiology. 2008 Dec 2 [Epub ahead of print].
15. S. Eda, J. Kaufmann, W. Roos, and S. Pohl Development of a new microparticle-enhanced turbidimetric assay for C-reactive protein with superior features in analytical sensitivity and dynamic range J Clin Lab Anal 12 1998 137 144 (Pubitemid 28208752)
16. P.M. Ridker Role of inflammatory biomarkers in prediction of coronary heart disease Lancet 358 2001 946 948 (Pubitemid 32913515)
17. B. Healy Endothelial cell dysfunction: an emerging endocrinophaty linked to the coronary disease J Am Coll Cardiol 16 1990 357 358 (Pubitemid 20245852)
18. F. Medina, J. De Haro, E. Martínez, A. Flórez, J.R. March, and F. Acín Relación de la dilatación de la arteria braquial mediada por flujo y el índice tobillo-brazo en pacientes con enfermedad arterial periférica Angiología 59 2007 55 61 (Pubitemid 351737970)
19. J. De Haro, F. Medina, E. Martínez, A. Flórez, C. Varela, and F. Acín Relación del tamaño del aneurisma de aorta abdominal asintomático con los niveles plasmáticos de Proteína C Reactiva Angiología. 59 2007 111 120 (Pubitemid 351737949)
20. H. Sülevman, B. Demircan, and Y. Karagöz Anti-inflammatory and side effects of cyclooxygenase inhibitors Pharmacol Rep 59 2007 247 258 (Pubitemid 47299726)
21. D.L. Sherman, J.F. Keaney, E.S. Blegelsen, S.J. Duffy, J.C. Coffman, and J.A. Vita Pharmacological concentrations of ascorbic acid are required for the beneficial effects of endothelial vasomotor function in hypertension Hypertension 35 2000 936 941
22. J.F. Keaney, and J.A. Vita Atherosclerosis, oxidative stress and antioxidant protection in endothelium-derived relaxing factor action Prog Cardiovasc Dis 38 1995 129 154
23. S. Verma, C.H. Wang, and S.H. Li A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis Circulation 106 2002 913 919 (Pubitemid 34925323)
24. A.D. Hingorani, J. Cross, and R.K. Kharbanda Acute systemic inflammation impairs endothelium-dependent dilatation in humans Circulation 102 2000 994 999 (Pubitemid 30657515)
25. L.J. Crofford COX-1 and COX-2 tissue espression: implications and predictions J Rheumatol 24 Suppl 49 1997 15 19 (Pubitemid 27314722)
26. M.R. Linton, and S. Fazio Cyclooxygenase-2 and atherosclerosis Curr Opin Lipidol 13 2002 497 504 (Pubitemid 35231929)
27. H. Wang, W.G. Ma, L. Tejada, H. Zhang, J.D. Morrow, and S.K. Das Rescue of female infertility from the loss of cyclooxygenase-2 by compensatory up-regulation of cyclooxygenase-1 is a function of genetic make-up J Biol Chem 279 2004 10649 10658 (Pubitemid 38372677)
28. C. Griffoni, E. Spisni, A. Strillacci, M. Toni, M.M. Bachschmid, and V. Tomasi Selective inhibition of prostacyclin synthase activity by rofecoxib J Cell Mol Med 11 2007 327 338 (Pubitemid 46693331)
29. J. Kreuzer, S. Denger, and L. Jahn LDL stimulates chemotaxis of human monocytes through a cyclooxygenase-dependent pathway Arterioscler Thromb Vasc Biol 16 1996 1481 1487 (Pubitemid 26427601)
30. J.A. Páramo, J.A. Rodríguez, O. Beloqui, and J. Orbe Monocyte cyclooxygenase-2 activity: a new therapeutic target for atherosclerosis? Curr Drug Targets Cardiovasc Haematol Disord 5 2005 303 311 (Pubitemid 41131701)
31. W.G. Haynes, and D.J. Webb Endothelin as a regulator of cardiovascular function in health and disease J Hypertens 16 1998 1081 1098 (Pubitemid 28334007)
32. J.A. Winkles, G.F. Alberts, E. Brogi, and P. Libby Endothelin-1 and endothelin receptor mRNA expression in normal and atherosclerotic human arteries Biochem Biophys Res Commun 191 1993 1081 1088 (Pubitemid 23231600)
33. A. Flórez, J. De Haro, C. Varela, and F. Acín En el origen de la enfermedad arterial periférica: papel de la endotelina en la disfunción endotelial Angiología 60 2008 395 401
34. A. Lerman, D. Holmes, and M. Bell Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans Circulation 92 1995 2426 2431